NCT00479817View on ClinicalTrials.gov

Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

July 5, 2007

Primary Completion Date

August 11, 2009

Study Completion Date

December 9, 2019

Conditions
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Interventions
DRUG

AMG 386

10mg/kg

DRUG

AMG 386

3 mg/kg

DRUG

Paclitaxel

Paclitaxel 80 mg/m2 IV QW (3 on/1 off)

DRUG

AMG 386 Placebo

AMG 386 Placebo

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY